- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2018
- Public Summary Document (PSD) November 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2018 PBAC Meeting - Word
Tofacitinib – November 2018
Tofacitinib: Tablet 5 mg; Xeljanz®
Last updated
1 March 2019